
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
NERVGEN PHARMA CORP. 9UA CA64082X2032 BAW/UFN
© 2024 Xetra Newsboard
Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,670 | 1,940 | 08.03. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mi | NervGen Pharma Corp.: NervGen Pharma to Present at the Virtual Life Science Investor Forum | Vancouver, British Columbia--(Newsfile Corp. - March 5, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics... ► Artikel lesen | |
19.02. | Nervgen Pharma Corp: Nervgen Pharma grants options to buy 627,200 shares | ||
18.02. | NervGen Pharma Corp.: NervGen Pharma Grants Stock Options | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics... ► Artikel lesen | |
06.02. | NervGen Pharma Corp.: NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury | Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics... ► Artikel lesen | |
29.01. | NervGen Pharma Corp.: NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference | Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today... ► Artikel lesen |